CreatorsPublishersAdvertisers

#Siteman Cancer Center

onclive.com

Dr. Van Tine on Next Steps With Catequentinib in Soft Tissue Sarcoma

Brian A. Van Tine, MD, PhD, discusses next steps with catequentinib (Anlotinib) in soft tissue sarcoma. Brian A. Van Tine, MD, PhD, associate professor, Department of Medicine, director, Sarcoma Program, Division of Medical Oncology, Washington University School of Medicine in St. Louis, and a medical oncologist, Siteman Cancer Center, discusses next steps with catequentinib (Anlotinib) in soft tissue sarcoma.
CANCER
KMOV

BJC offering free flu shots this weekend

ST. LOUIS (KMOV.com) - BJC will be offering free flu shots at different locations across the St. Louis area. The vaccinations will be offered to St. Louis area residents 6 months and older. Those 65 and older may receive a high dose of the vaccine while supplies last. Health insurance is not required. BJC is urging everyone to get their flu shot in light of the COVID-19 pandemic.
SAINT LOUIS, MO
Picture for BJC offering free flu shots this weekend
TRENDING TOPICS
Clay County Times Democrat

Alice Rosetta Bush

With profound sadness we announce the passing of Alice Rosetta Bush, our loving and devoted mother. Rose went to be with our Lord in His heavenly home on Aug. 11, 2021. She was in her 79th year of life. Married to Joseph Bush for the past thirty-four years. She was...
OBITUARIES
onclive.com

Catequentinib Proves Efficacious, Well Tolerated in Synovial Sarcoma

Brian A. Van Tine, MD, PhD, discusses the study design, key findings, adverse events, and research beyond the APROMISS study. Catequentinib (Anlotinib) significantly prolonged progression-free survival (PFS) in patients with synovial sarcoma who experienced disease progression following anthracycline-containing therapies, according to Brian A. Van Tine, MD, PhD, who added that the agent represents a potentially safer option than existing therapies available to this population.
SCIENCE
YOU MAY ALSO LIKE